tradingkey.logo

tradingkey.logo
怜玢


Niagen Bioscience Inc

NAGE
りォッチリストに远加
2.070USD
0.0000.00%
終倀 11-06 16:00ET
163.80M時䟡総額
8.86盎近12ヶ月PER

Niagen Bioscience Incに぀いお 䌁業名

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Niagen Bioscience Inc プロフィヌル


䌁業コヌドNAGE
䌚瀟名Niagen Bioscience Inc
䞊堎日Jun 25, 2007
最高経営責任者「CEO」Fried (Robert N)
埓業員数104
蚌刞皮類Ordinary Share
決算期末Jun 25
本瀟所圚地10900 Wilshire Blvd Suite 600
郜垂LOS ANGELES
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号90024
電話番号13103886706
りェブサむトhttps://www.niagenbioscience.com/
䌁業コヌドNAGE
䞊堎日Jun 25, 2007
最高経営責任者「CEO」Fried (Robert N)

Niagen Bioscience Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
13.85K
+30.73%
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
13.85K
+30.73%
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
4.57K
+50.69%
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
4.57K
+50.69%
Mr. Frank L. Jaksch, Jr.
Mr. Frank L. Jaksch, Jr.
Chairman of the Board
Chairman of the Board
--
--
Mr. Robert N. (Rob) Fried
Mr. Robert N. (Rob) Fried
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Wendy Yu
Ms. Wendy Yu
Independent Director
Independent Director
--
--
Mr. Gary Ng
Mr. Gary Ng
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
13.85K
+30.73%
Mr. Ozan Pamir
Mr. Ozan Pamir
Chief Financial Officer
Chief Financial Officer
13.85K
+30.73%
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Lead Independent Director
Lead Independent Director
7.00K
--
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
4.57K
+50.69%
Mr. Carlos Luis Lopez
Mr. Carlos Luis Lopez
Senior Vice President, General Counsel
Senior Vice President, General Counsel
4.57K
+50.69%

よくある質問

Niagen Bioscience Incの䞊䜍5名の株䞻は誰ですか


Niagen Bioscience Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Ozan Pamir
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。